http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
최영배,이춘희,박창순 한국통신학회 1997 정보와 통신 Vol.14 No.12
정보통신 시장의 개방이 가속화 되고 사업자간의 경쟁이 치열해 짐에 따라, 이에 따른 서비스 관리의 필요성이 최근 중요한 문제로 대두되게 되었다. 지금까지는 정보통신 산업계에서 망 관리의 측면이 많이 강조되어 왔으나, 최근 고객의 요구가 다양해 짐에 따라 이를 보다 효율적으로 만족시켜 주기 위해 서비스 제공자 중심이 아닌 고객중심의 새로운 체제로 전환이 불가피하게 되었다. 본 고에서는 이러한 고객의 요구를 만족시켜 주는 데 핵심 기술이라고는 할 수 있는 정보통신 서비스 관리 기술에 대해 Network Management Forum (NMF)의 Service Management Business Process Model을 중심으로 알아보기로 한다.
한국에 있어서의 히이트 펌프계의 최적 설계 조건에 관한 연구
최영배,Choe, Yeong-Bae 대한설비공학회 1981 설비저널 Vol.10 No.4
This paper presents, the result of the study for the fluctuant temperature of the out-side air adopting the heat pump system in seoul, Taejean, Taegu, Busan and Jejeu among principle cities in korea for the purpose of checking the heating capacity, Heat pump capacity (outlet capacity), Coefficient of performance and running cost in comparison with the supporting the energy for the boiler's operation. According to the supply temperature changes of the out door coil by the out side air-return air mixing ratio, the Coefficient of performance is increased from 3. 1 to 5.0. Particularly, in Taegu, it is necessary to adopt the heat pump system against the supplement heat supply on the full outside air intake in January of the heating period, and it was recognized that the running cost is cheaper than that of the Boiler use. At the same time, if it is able to get $25\%$ of return air of the inside in the Seoul, it could be saved its costs when we use the supplementary boiler. And I think it is necessary to the development.
최영배,이지원,성기웅,구홍회,김희진,유건희 대한의학회 2019 Journal of Korean medical science Vol.34 No.6
Background: The impact of early peripheral blood chimerism on the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is unclear. We aimed to determine whether day 14 peripheral blood chimerism after allo-HSCT predicts outcomes in patients with non-malignant diseases. Methods: Data from 56 patients who received allo-HSCT between April 2007 and March 2016 were retrospectively analyzed. Chimerism was evaluated using short-tandem repeat polymerase chain reaction, with mixed chimerism (MC) defined as greater than 1% recipient cells which was further categorized into low-level MC (> 1% and < 15% of recipient-derived cells) and high-level MC (≥ 15% of the recipient-derived cells). Results: Thirty-six patients showed complete donor chimerism (CC), 14 low-level MC, and 6 high-level MC at day 14 post-transplant. The estimated 5-year event-free survival (EFS) was higher in the CC or low-level MC groups than in the high-level MC group (86.1% vs. 71.4% vs. 33.3%; P = 0.001). In BM or peripheral blood stem cell (BM/PBSC) transplants, the 5-year EFS was higher in the CC or low-level MC group than in the high-level MC group (93.1% vs. 66.7% vs. 0%; P < 0.001). However, in cord blood transplants, the 5-year OS and EFS according to the day 14 peripheral blood chimerism did not reach statistical significance. Conclusion: Although CC is not always necessary after allo-HSCT for non-malignant diseases, our data suggest that day 14 peripheral blood chimerism may predict outcomes in patients with non-malignant diseases who underwent BM/PBSC transplants.
최영배,이은상,이지원,유건희,성기웅,구홍회 대한의학회 2016 Journal of Korean medical science Vol.31 No.7
Despite increasing evidence that high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT) might improve the survival of patients with high-risk or recurrent solid tumors, therapy effectiveness for bone and soft tissue sarcoma treatment remains unclear. This study retrospectively investigated the feasibility and effectiveness of HDCT/auto-SCT for high-risk or recurrent bone and soft tissue sarcoma. A total of 28 patients (18 high-risk and 10 recurrent) underwent single or tandem HDCT/auto-SCT between October 2004 and September 2014. During follow-up of a median 15.3 months, 18 patients exhibited disease progression and 2 died of treatment-related toxicities (1 veno-occlusive disease and 1 sepsis). Overall, 8 patients remained alive and progressionfree. The 3-year overall survival (OS) and event-free survival (EFS) rates for all 28 patients were 28.7% and 26.3%, respectively. In the subgroup analysis, OS and EFS rates were higher in patients with complete or partial remission prior to HDCT/auto-SCT than in those with worse responses (OS, 39.1% vs. 0.0%, P = 0.002; EFS, 36.8% vs. 0.0%, P < 0.001). Therefore, careful selection of patients who can benefit from HDCT/auto-SCT and maximal effort to reduce tumor burden prior to treatment will be important to achieve favorable outcomes in patients with high-risk or recurrent bone and soft tissue sarcomas.
최영배,박남훈,이계상,Choe, Yeong-Bae,Park, Nam-Hun,Lee, Gye-Sang 한국전자통신연구원 1996 전자통신동향분석 Vol.11 No.3
세계의 통신 시장이 개방되는 추세에 있고, 통신에 관한 규제가 완화됨에 따라 떠오르는 문제는 여러 가지 있겠으나 가장 큰 문제는 역시 표준화와 이에 따른 상호 운용성(interoperability)의 문제가 아닌가 생각한다. 본 고에서는 통신 분야의 서비스 관리에 있어서 세계적으로 주도적인 활동을 하고 있고, 그 중요성이 점차 부각되고 있는 NMF(Network Management Forum)의 역할에 대하여 소개하고자 하였다.
최영배,황성운,이준석,윤기송,김명준,Choi, Y.B.,Hwang, S.O.,Lee, J.S.,Yoon, K.S.,Kim, M.J. 한국전자통신연구원 1999 전자통신동향분석 Vol.14 No.6
IPSEC (Internet Protocol Security) is a network layer security protocol that is designed to support secure TCP/IP environment over the Internet considering flexibility, scalability, and interoperability. IPSEC primarily supports security among hosts rather than users unlike the other security protocols. Recently, IPSEC is emphasized as one of the important security infrastructures in the NGI (Next Generation Internet). It also has suitable features to implement VPN (Virtual Private Network) efficiently and its application areas are expected to grow rapidly. In this paper, the basic concepts and related standard documents of IPSEC will be introduced.
Clinical Significance of Persistent Tumor in Bone Marrow during Treatment of High-risk Neuroblastoma
최영배,배고은,이나희,김정선,이수현,유건희,성기웅,구홍호 대한의학회 2015 Journal of Korean medical science Vol.30 No.8
The records of 63 high-risk neuroblastoma patients with bone marrow (BM) tumors at diagnosis were retrospectively reviewed. All patients received nine cycles of induction chemotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT). Follow-up BM examination was performed every three cycles during induction chemotherapy and every three months for one year after the second HDCT/auto-SCT. BM tumor cells persisted in 48.4%, 37.7%, 23.3%, and 20.4% of patients after three, six, and nine cycles of induction chemotherapy and three months after the second HDCT/auto-SCT, respectively. There was no difference in progression-free survival (PFS) rate between patients with persistent BM tumor and those without during the induction treatment. However, after tandem HDCT/auto-SCT, the PFS rate was worse in patients with persistent BM tumor than in those without (probability of 5-yr PFS 14.7% ± 13.4% vs. 64.2% ± 8.3%, P = 0.009). Persistent BM tumor during induction treatment is not associated with a worse prognosis when intensive tandem HDCT/auto-SCT is given as consolidation treatment. However, persistent BM tumor after tandem HDCT/ auto-SCT is associated with a worse prognosis. Therefore, further treatment might be needed in patients with persistent BM tumor after tandem HDCT/auto-SCT.